The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

BD has found a new home for its biosciences and diagnostics divisions at the lab equipment maker Waters Corporation, through ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

Essa Pharma, which had been resisting pressure from activist investors to wind down operations, has now agreed a deal to ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R)-selective agonist ...

The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...

Mendaera has claimed an FDA clearance for its handheld robotic needle delivery system, for precision placement guided by ...

Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, ...

Karyopharm Therapeutics is laying off 20% of staffers as efforts to secure a strategic alternative have turned up short. | ...